Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Bavarian Nordic (BVNRY : OTC)

• Company Description    Bavarian Nordic A/S is a biotechnology company. It focused on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases. The company's product pipeline consists of IMVAMUNE(R), PROSTVAC (R), MVA-BN Brachyury, CV-301, MVA-BN Filo which are in clinical trial stage. Bavarian Nordic A/S is headquartered in Kvistgaard, Denmark. Number of Employees: 1,611

• Price / Volume Information    Yesterday's Closing Price: $9.27 Daily Weekly Monthly 20 Day Moving Average: 1,735 shares Shares Outstanding: 236.57 (millions) Market Capitalization: $2,192.95 (millions) Beta: 1.36 52 Week High: $14.60 52 Week Low: $6.60 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 0.11% -3.65% 12 Week 23.11% 1.30% Year To Date 6.48% -0.09%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL Philip Heymans Alle 3 - Hellerup,G7 2900 DNK ph: 45-3326-8383 fax: 45-3326-8380 investor@bavarian-nordic.com http://www.bavarian-nordic.com

• General Corporate Information    Officers Paul Chaplin - Chief Executive Officer and President Anders Gersel Pedersen - Deputy Chairman Luc Debruyne - Chairman of the Board Henrik Juuel - Chief Financial Officer and Executive Vice Preside Frank Verwiel - Director Peer Information Bavarian Nordic (CORR.) Bavarian Nordic (RSPI) Bavarian Nordic (CGXP) Bavarian Nordic (BGEN) Bavarian Nordic (GTBP) Bavarian Nordic (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 071771109 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/28/25 Share - Related Items Shares Outstanding: 236.57 Most Recent Split Date: (:1) Beta: 1.36 Market Capitalization: $2,192.95 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $1.05 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: 0.00 Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/28/25

• Fundamental Ratios P/E Current FY Estimate: 8.83 Trailing 12 Months: 11.59 PEG Ratio: - Price Ratios Price/Book: 1.34 Price/Cash Flow: 9.15 Price / Sales: 2.45 EPS Growth vs. Year Ago Period: 285.71% vs. Previous Quarter: -72.34% Sales Growth vs. Year Ago Period: 56.83% vs. Previous Quarter: -36.60% ROE 06/30/25 - - 03/31/25 - 11.89 12/31/24 - 9.11 ROA 06/30/25 - - 03/31/25 - 9.32 12/31/24 - 6.92 Current Ratio 06/30/25 - - 03/31/25 - 2.81 12/31/24 - 2.07 Quick Ratio 06/30/25 - - 03/31/25 - 1.44 12/31/24 - 1.24 Operating Margin 06/30/25 - - 03/31/25 - 21.11 12/31/24 - 17.12 Net Margin 06/30/25 - - 03/31/25 - 21.11 12/31/24 - 17.12 Pre-Tax Margin 06/30/25 - - 03/31/25 - 21.18 12/31/24 - 16.99 Book Value 06/30/25 - - 03/31/25 - 6.89 12/31/24 - 6.99 Inventory Turnover 06/30/25 - - 03/31/25 - 1.33 12/31/24 - 1.39 Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.11 12/31/24 - 0.11

Powered by Zacks Investment Research ©